Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Wedbush

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) was downgraded by equities researchers at Wedbush from a "strong-buy" rating to a "hold" rating in a research report issued on Thursday, MarketBeat.com reports. They presently have a $8.00 price target on the stock, down from their prior price target of $13.00. Wedbush's price target points to a potential upside of 1.46% from the company's previous close.

A number of other equities analysts have also weighed in on the company. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. HC Wainwright decreased their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Friday, March 14th. Finally, William Blair downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $11.50.

Vigil Neuroscience Stock Down 0.1%

NASDAQ:VIGL traded down $0.01 during mid-day trading on Thursday, hitting $7.89. 1,668,133 shares of the company traded hands, compared to its average volume of 641,017. The stock's fifty day moving average price is $2.31 and its 200-day moving average price is $2.31. Vigil Neuroscience has a one year low of $1.31 and a one year high of $7.95. The firm has a market cap of $368.01 million, a price-to-earnings ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. Equities analysts predict that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

A number of institutional investors have recently modified their holdings of the business. BVF Inc. IL grew its position in shares of Vigil Neuroscience by 121.3% during the 1st quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock valued at $7,144,000 after acquiring an additional 2,200,000 shares during the period. 683 Capital Management LLC boosted its holdings in shares of Vigil Neuroscience by 24.3% during the 1st quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock worth $3,097,000 after purchasing an additional 340,000 shares during the last quarter. Aberdeen Group plc lifted its holdings in Vigil Neuroscience by 226.3% in the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock valued at $3,070,000 after acquiring an additional 1,196,048 shares during the last quarter. Blair William & Co. IL lifted its holdings in Vigil Neuroscience by 219.1% in the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock valued at $1,840,000 after acquiring an additional 709,677 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its holdings in Vigil Neuroscience by 16.1% in the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company's stock valued at $1,195,000 after acquiring an additional 97,580 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.